COVID‐19: Consider IL‐6 receptor antagonist for the therapy of cytokine storm syndrome in SARS‐CoV‐2 infected patients. Issue 11 (19th June 2020)

• Record Type: Journal Article
• Authors: Chakraborty, Chiranjib; Sharma, Ashish Ranjan; Bhattacharya, Manojit; Sharma, Garima; Lee, Sang‐Soo; Agoramoorthy, Govindasamy
• Other Names: Luo Guangxiang (George) guestEditor.; Ly Hinh guestEditor.; Gao Shou‐Jiang guestEditor.
• Is Part Of: Journal of medical virology. Volume 92:Issue 11(2020)
• Page Start: 2260
• Page End: 2262
• Publication Date: 2020-06-19
• Subjects: cytokine storm -- IL‐6R antagonist -- sarilumab -- therapeutic option -- tocilizumab; Virology -- Periodicals; 616
• DOI: 10.1002/jmv.26078
• Languages: English
• ISSNs: 0146-6615

Abstract

Abstract: COVID‐19 leads to mortality of several patients and the cytokine storm is reportedly critical in the patients. To reduce the cytokine storm, we would like to propose the interleukin (IL) 6 receptor (IL‐6R) antagonist therapy for the COVID‐19 patients. Two humanized monoclonal antibodies are in clinical trial following IL‐6R antagonist therapies namely tocilizumab and sarilumab. However, researchers and physicians should look for more IL‐6R antagonists for the therapy of cytokine storm syndrome severe acute respiratory syndrome coronavirus 2 infected persons to enhance the therapeutic options for cytokine storm. Highlights: Cytokine storm syndrome or cytokine release syndrome (CRS) is often observed in severe COVID‐19 patients. CRS may be the leading cause of the deaths of severe COVID‐19 patients. IL6 receptor antagonist molecules may be helpful for the therapy for containing CRS. Two humanized monoclonal antibodies (IL6 receptor antagonists), namely, tocilizumab and sarilumab, are in the clinical trials for the treatment of CRS of COVID‐19 patients.